Novel ADC Delivers Responses and a Manageable Safety Profile in R/R Non-Hodgkin Lymphoma
Zilovertamab vedotin was tolerable and generated early efficacy signals in patients with relapsed/refractory non-Hodgkin lymphoma.
Source: onclive.com
Page 27 - Michael Wang News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Michael Wang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Michael Wang Today - Breaking & Trending Today
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.
Source: onclive.com
Risk-Adapted Treatment Approach Produces Durable Remissions in MCL
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Source: cancertherapyadvisor.com
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023
In TRANSCEND FL, 97% of patients with relapsed or refractory follicular lymphoma treated with Breyanzi achieved a response, with 94% achieving a complete response, and 81.9% of responders in ongoing... | June 17, 2023
Source: marketscreener.com
Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023 | Business
PRINCETON, N.J.--(BUSINESS WIRE)--Jun 17, 2023--
Source: maryvilleforum.com